Biopolym. Cell. 2010; 26(6):508-511.
Bioorganic Chemistry
Inhibition of in vitro transcription by 2-arylidene derivatives of thiazolo[3,2-α]benzimidazol-3(2H)-one
1Palchykovska L. G., 1Alexeeva I. V., 1Negrutska V. V., 1Kostyuk Yu. K., 1Indychenko T. M., 1Kostenko O. M., 1Kryvorotenko D. V., 1Shved A. D., 1Dubey I. Ya.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680


Aim. To evaluate a series of 2-substituted thiazolo[3,2-α]benzimidazolones as potential transcription inhibitors. Methods. Compounds were tested in a model transcription system based on T7 RNA polymerase. Results. The testing revealed a number of compounds able to inhibit transcription at micromolar concentrations. The most active inhibitor was dihydroxy derivative BT29 with IC50 = 1.6 μM. Conclusions. Structure-functional dependence of the activity of tested compounds as transcription inhibitors was found. The key structural feature required for their high activity is a presence of hydroxy or dialkylamino group at p- or m-position of arylidene fragment.
Keywords: thiazolo[3,2-α]benzimidazolones, transcription inhibitors, T7 RNA polymerase


[1] Jung D., Choi Y., Uesugi M. Small organic molecules that modulate gene transcription Drug Discov. Today 2006 11, N 9–10:452-457.
[2] Ebalunode J. O., Weifan Z. Molecular shape technologies in drug discovery: methods and applications Curr. Top. Med. Chem 2010 10, N 6:669–679.
[3] Tunitskaya V. L., Kochetkov S. N. Structural-functional analysis of bacteriophage T7 RNA polymerase. Biochemistry (Moscow). 2002; 67(10):1124–1135.
[4] Kennedy W. P., Momand J. R., Yin Y. W. Mechanism for de novo RNA synthesis and initiating nucleotide specificity by T7 RNA polymerase J. Mol. Biol 2007 370, N 2:256– 268.
[5] Sousa R., Chung Y. J., Rose J. P., Wang B.-C. Crystal structure of bacteriophage T7 RNA polymerase at 3.3 C resolution Nature 1993 364, N 6438:593–599.
[6] McAllister W. T., Raskin C. A. The phage RNA polymerases are related to DNA polymerases and reverse transcriptases Mol. Microbiol 1993 10, N 1:1–6.
[7] White R. J., Phillips D. R. Sequence-dependent termination of bacteriophage T7 transcription in vitro by DNA-binding drugs Biochemistry 1989 28, N 10:4277–4283.
[8] Puvvada M. S., Forrow S. A., Hartley J. A., Stephenson P., Gibson I., Jenkins T. C., Thurston D. E. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNAbinding pyrrolo[2,1-c][1,4]benzodiazepines Biochemistry 1997 36, N 9:2478–2484.
[9] Piestrzeniewich M., Studzian K., Wilmanska D., Plucienniczak G., Gniazdowski M. Effect of DNA-interacting drugs on phage T7 RNA polymerase. Acta Biochim. Pol. 1998; 45(1):127–132.
[10] Chen X., Gao F., Zhou Z.-X., Yang W.-Y., Gao L.-T., Ji L.-N. Effect of ancillary ligands on the topoisomerases II and transcription inhibition activity of polypyridyl ruthenium(II) complexes J. Inorg. Biochem 2010 104, N 5:576– 582.
[11] Palchykovska L. G., Alexeeva I. V., Kostina V. G., Platonov M. O., Negrutska V. V., Deriabin O. M., Tarasov O. A., Shved A. D. New amides of phenazine-1-carboxylic acid: antimicrobial activity and structure-activity relationship. Ukr Biokhim Zh. 2008; 80(3):140–147.
[12] Stankiewicz-Drogon A., Palchykovska L. G., Kostina V. G., Alexeeva I. V., Shved A. D., Boguszewska-Chachulska A. M. New acridone-4-carboxylic acid derivatives as potential inhibitors of Hepatitis C virus infection Bioorg. Med. Chem 2008 16, N 19:8846–8852.
[13] Palchykovska L. G., Alexeeva I. V., Platonov M. O., Kostenko O. M., Usenko L. S., Negrutska V. V., Shved A. D. New 1, 2,4-triazine bearing compounds: molecular modeling, synthesis and biotesting. Biopolym. Cell. 2009; 25, N 6 P. 491–499.
[14] Mavrova A. T., Anichina K. K., Vuchev D. I., Tsenov J. A., Kondeva M. S., Micheva M. K. Synthesis and antitrichinellosis activity of some 2-substituted-[1,3]thiazolo[3,2-]benzimidazol-3(2H)-ones Bioorg. Med. Chem 2005 13, N 19:5550–5559.
[15] Al-Rashood K. A., Abdel-Aziz H. A. Thiazolo[3,2-]benzimidazoles: synthetic strategies, chemical transformations and biological activities Molecules 2010 15, N 6:3775– 3815.
[16] Pat. UK Application GB2376944 31.12.2002. Polycyclic heterocyclic compounds and their therapeutic use. N. M. Allanson, B. W. Leslie, S. Thomson.
[17] Pat. USA. Application 20070015768 01.18.2007. Ubiquitin ligase inhibitors and methods related thereto. I. Alroy, Sh. Tuvia, Y. Reiss, O. Levi-Hacham.
[18] Leyssen P., De Clercq E., Neyts J. Molecular strategies to inhibit the replication of RNA viruses Antivir. Res 2008 78, N 1:9–25.
[19] Chimirri A., Monforte P., Musumeci L., Rao A., Zappala M., Monforte A.-M. Synthesis and antitumour activity of 1H,3Hthiazolo[3,4-]benzimidazole derivatives Arch. Pharm 2001 334, N 6:203–208.